Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with the heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during the shortage of vaccine supply are available. Forty-four cancer patients who previously received the heterologous Coro...

Full description

Bibliographic Details
Main Authors: Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun, Suebpong Tanasanvimon
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Vaccines
Subjects:
COVID-19 vaccine
booster vaccine
third dose vaccine
omicron
heterologous primary vaccination
CoronaVac
Online Access:https://www.mdpi.com/2076-393X/10/10/1613

Internet

https://www.mdpi.com/2076-393X/10/10/1613

Similar Items